secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2026-06-30T12:03:55+00:00
Accession:  0001753926-26-001109
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical receives HREC approval to initiate Phase 1 trial of NPM-139 semaglutide implant for obesity
--------------------------------------------------------------------------------

- Received approval from Bellberry HREC in Australia to start SLIM-1 Phase 1 trial of NPM-139 semaglutide implant.
- SLIM-1 trial initiation expected mid-2026; builds on prior Phase 1 success with NPM-119 exenatide implant in 2025.
- Company plans SLIM-2 dose-ranging efficacy trial pending SLIM-1 results to accelerate NPM-139 development.
- CEO cites strong market demand for miniature, reversible GLP-1 implant technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392626001109/0001753926-26-001109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392626001109/vani-20260624.htm
  HTML page:      https://secwatch.observer/filing/0001753926-26-001109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer